Innate Pharma Files 6-K
Ticker: IPHYF · Form: 6-K · Filed: Feb 27, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Innate Pharma filed a 6-K on Feb 27, 2025, nothing major, just housekeeping.
AI Summary
Innate Pharma SA filed a Form 6-K on February 27, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates but serves as a notification to the SEC.
Why It Matters
This filing indicates Innate Pharma is fulfilling its reporting obligations as a foreign private issuer, which is standard procedure for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial or operational information.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- February 27, 2025 (date) — Filing Date
- 001-39084 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.
What specific information was included in the press release dated February 27, 2025?
The filing lists 'Press Release dated February 27, 2025' as Exhibit 1.1, but the content of the press release is not detailed within this 6-K document itself.
Does this filing indicate any new financial results for Innate Pharma?
No, this Form 6-K does not appear to contain new financial results; it primarily serves to attach a press release.
What is Innate Pharma's primary business?
Innate Pharma SA is in the business of Biological Products (excluding diagnostic substances), as indicated by its SIC code [2836].
Where is Innate Pharma's principal executive office located?
Innate Pharma's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 27, 2025 regarding Innate Pharma SA (IPHYF).